Keros Therapeutics Files 8-K on Executive Changes and Financials
Ticker: KROS · Form: 8-K · Filed: May 28, 2024 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | May 28, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $40,000, $5,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, officer-changes
Related Tickers: KROS
TL;DR
Keros Therapeutics (KROS) filed an 8-K detailing executive changes and financial updates.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on May 28, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. The filing also includes financial statements and exhibits. The earliest event reported was on May 23, 2024.
Why It Matters
This filing provides updates on the company's leadership and financial reporting, which are crucial for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine filing reporting on corporate governance and financial statements, not indicating any immediate operational or financial distress.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- May 23, 2024 (date) — Date of earliest event reported
- May 28, 2024 (date) — Date of report
- 001-39264 (company) — SEC File Number
- 81-1173868 (company) — I.R.S. Employer Identification No.
- 1050 Waltham Street, Suite 302 (location) — Principal executive offices address
- Lexington, Massachusetts (location) — Principal executive offices city and state
- 02421 (location) — Principal executive offices zip code
- ( 617 ) 314-6297 (phone_number) — Registrant's telephone number
FAQ
What specific items are being reported in this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and includes financial statements and exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is May 23, 2024.
What is the principal executive office address for Keros Therapeutics, Inc.?
The principal executive office address is 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
What is the SEC file number for Keros Therapeutics, Inc.?
The SEC file number for Keros Therapeutics, Inc. is 001-39264.
What is the IRS Employer Identification Number for Keros Therapeutics, Inc.?
The IRS Employer Identification Number for Keros Therapeutics, Inc. is 81-1173868.
Filing Stats: 919 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2024-05-28 16:02:37
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
- $40,000 — rector compensation policy to receive a $40,000 annual cash retainer for his service on
- $5,000 — ell as an additional annual retainer of $5,000 for service as a member of the Nominati
Filing Documents
- kros-20240523.htm (8-K) — 45KB
- exhibit991jjbienaimepr.htm (EX-99.1) — 7KB
- 0001664710-24-000041.txt ( ) — 180KB
- kros-20240523.xsd (EX-101.SCH) — 2KB
- kros-20240523_lab.xml (EX-101.LAB) — 22KB
- kros-20240523_pre.xml (EX-101.PRE) — 13KB
- kros-20240523_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated M ay 28 , 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: May 28, 2024